Masaki Tomita1, Takanori Ayabe2, Ryo Maeda2, Kunihide Nakamura3. 1. Department of Thoracic and Breast Surgery, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan mtomita@med.miyazaki-u.ac.jp. 2. Department of Thoracic and Breast Surgery, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan. 3. Department of Cardiovascular Surgery, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan.
Abstract
BACKGROUND: The systemic immune-inflammation index (SII) is reported to be associated with clinical outcomes and has been proven to be a promising prognostic indicator in several solid tumor types. To the best of our knowledge, however, no studies regarding SII in patients with resectable non-small cell lung cancer (NSCLC) are available. MATERIALS AND METHODS: Three hundred forty-one patients with NSCLC who underwent surgery at our Institution between 2008 and 2012 were included. The SII was calculated using the formula: platelet count × neutrophil/lymphocyte count. The optimal cut-off value was calculated using the Cutoff Finder (http://molpath.charite.de/cutoff). Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. RESULTS: The optimal cut-off value was 471.2×109/l for SII. A low SII was associated with female gender, never smoking status, adenocarcinoma histology, higher pathological TNM stage and low level of serum C-reactive protein, but not age, serum carcinoembryonic antigen or cytokeratin 19 fragment level. Patients of the low SII group had a significantly better 5-year overall survival than those with high SII (83.61% vs. 60.39%, p<0.001). Multivariate analysis revealed that the SII was a significant independent predictive indicator for cancer-specific survival (p=0.007). CONCLUSION: This is the first study to demonstrate that the SII could represent an independent prognostic factor for patients with resectable NSCLC. Copyright
BACKGROUND: The systemic immune-inflammation index (SII) is reported to be associated with clinical outcomes and has been proven to be a promising prognostic indicator in several solid tumor types. To the best of our knowledge, however, no studies regarding SII in patients with resectable non-small cell lung cancer (NSCLC) are available. MATERIALS AND METHODS: Three hundred forty-one patients with NSCLC who underwent surgery at our Institution between 2008 and 2012 were included. The SII was calculated using the formula: platelet count × neutrophil/lymphocyte count. The optimal cut-off value was calculated using the Cutoff Finder (http://molpath.charite.de/cutoff). Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. RESULTS: The optimal cut-off value was 471.2×109/l for SII. A low SII was associated with female gender, never smoking status, adenocarcinoma histology, higher pathological TNM stage and low level of serum C-reactive protein, but not age, serum carcinoembryonic antigen or cytokeratin 19 fragment level. Patients of the low SII group had a significantly better 5-year overall survival than those with high SII (83.61% vs. 60.39%, p<0.001). Multivariate analysis revealed that the SII was a significant independent predictive indicator for cancer-specific survival (p=0.007). CONCLUSION: This is the first study to demonstrate that the SII could represent an independent prognostic factor for patients with resectable NSCLC. Copyright
Authors: Marek Z Wojtukiewicz; Ewa Sierko; Dominika Hempel; Stephanie C Tucker; Kenneth V Honn Journal: Cancer Metastasis Rev Date: 2017-06 Impact factor: 9.264
Authors: Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze Journal: Oncoimmunology Date: 2019-01-22 Impact factor: 8.110